The core domain of hepatitis C virus glycoprotein E2 generates potent cross‐neutralizing antibodies in guinea pigs

A vaccine that prevents hepatitis C virus (HCV) infection is urgently needed to support an emerging global elimination program. However, vaccine development has been confounded because of HCV's high degree of antigenic variability and the preferential induction of type‐specific immune responses...

Descripción completa

Detalles Bibliográficos
Autores principales: Vietheer, Patricia T., Boo, Irene, Gu, Jun, McCaffrey, Kathleen, Edwards, Stirling, Owczarek, Catherine, Hardy, Matthew P., Fabri, Louis, Center, Rob J., Poumbourios, Pantelis, Drummer, Heidi E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408392/
https://www.ncbi.nlm.nih.gov/pubmed/27997681
http://dx.doi.org/10.1002/hep.28989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408392/
https://www.ncbi.nlm.nih.gov/pubmed/27997681
http://dx.doi.org/10.1002/hep.28989

Ejemplares similares